June 25, 2026 · Form 4 insider transaction
Thomas John Charles sold 1,000 shares of Krystal Biotech, Inc. at $347.27 per share, a transaction worth $347.3K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
The acquisition and sale of shares of the Company's common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. All transactions contemplated by the plan have been completed, and the plan has terminated in accordance with its terms.